Brain calcification is more than a radiographic finding, it’s a devastating driver of seizures, migraines, and cognitive decline in rare CNS diseases like Sturge-Weber Syndrome and Tuberous Sclerosis.
At ZY Therapeutics, we’re developing Kamini (ZY-001), an oral formulation of etidronate designed to target brain calcium deposits. This is a novel disease-modifying approach with the potential to transform outcomes for patients who currently have no FDA-approved options.
We’re excited about the journey ahead and grateful to the communities and foundations who continue to support innovation in rare disease.
